Your session is about to expire
← Back to Search
Vitamin Supplement
NAD Therapy for Mild Cognitive Impairment
Phase 1 & 2
Waitlist Available
Led By Christopher R Martens, Ph.D.
Research Sponsored by University of Delaware
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and 12 weeks
Awards & highlights
Study Summary
This trial will test whether nicotinamide riboside (NR) can improve memory and brain blood flow in older adults with low memory abilities. If successful, this could be a safe and effective way to decrease age-related memory loss.
Who is the study for?
This trial is for older adults aged 60-90 with mild cognitive impairment, specifically those who have memory issues but can still score above 24 on the MMSE. Participants should not have significant medical conditions like heart disease or cancer, neurological disorders, a history of substance abuse, major psychiatric disorders, or be taking medications that affect cognition.Check my eligibility
What is being tested?
The study is testing whether Niagen®, a nutritional supplement containing nicotinamide riboside (NR), can improve memory and brain blood flow in participants compared to a placebo. The goal is to find an effective strategy to reduce age-related memory decline.See study design
What are the potential side effects?
While specific side effects are not listed here, as Niagen® is generally considered safe and cost-effective as a nutritional supplement, potential side effects could include digestive discomfort or skin flushing.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline and 12 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and 12 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change from baseline in cognitive scores at 12 weeks
Secondary outcome measures
Change from baseline in aortic stiffness at 12 weeks
Change from baseline in blood pressure at 12 weeks
Change from baseline in cerebrovascular reactivity at 12 weeks
+1 moreOther outcome measures
Change from baseline in brain volume at 12 weeks
Change from baseline in functional brain connectivity at 12 weeks
Change from baseline in neuronal activation at 12 weeks
+1 moreTrial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Nicotinamide RibosideExperimental Treatment1 Intervention
Niagen® (ChromaDex, Inc.) 500 mg, twice daily
Group II: PlaceboPlacebo Group1 Intervention
placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Niagen®
2018
Completed Phase 2
~70
Find a Location
Who is running the clinical trial?
University of DelawareLead Sponsor
154 Previous Clinical Trials
25,147 Total Patients Enrolled
National Institute on Aging (NIA)NIH
1,671 Previous Clinical Trials
28,016,999 Total Patients Enrolled
Christopher R Martens, Ph.D.Principal InvestigatorUniversity of Delaware
3 Previous Clinical Trials
76 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have a neurological or autoimmune condition that affects your thinking and memory, such as Parkinson's disease, epilepsy, multiple sclerosis, a brain injury, or a large stroke.You have had a head injury causing a concussion within the past 2 years, and you have had 3 or more concussions in your lifetime.You have serious medical conditions like heart disease, cancer, or kidney failure.You have had cancer in the past.You have a problem with using drugs or alcohol, and it affects your daily life.You are currently taking medications for dementia or other drugs that can affect your thinking abilities.You have smoked cigarettes or marijuana in the last 3 months.You have been diagnosed with a serious mental illness like schizophrenia, bipolar disorder, or major depression within the past two years.
Research Study Groups:
This trial has the following groups:- Group 1: Placebo
- Group 2: Nicotinamide Riboside
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What is the ideal candidate for this clinical trial?
"This study, which is currently enrolling 58 individuals aged 60-90 that have mild cognitive impairment, also requires that patients meet the following additional criteria: having cognitive function scores indicative of amnestic mild cognitive impairment from a pre-screening evaluation; being between the ages of 60 and 90 years old; and having an MMSE score >24 at the time of initial consent."
Answered by AI
Are people who are under 50 years old allowed to participate in this clinical trial?
"Eligibility for this study is restricted to those aged 60-90. There are 24 ongoing clinical trials involving patients who are younger than 18 and 567 for people 65 and older."
Answered by AI
Can new volunteers still sign up for this drug trial?
"Yes, this information is available on clinicaltrials.gov. The trial was posted on December 1st, 2018 and was updated as recently as August 30th, 2020."
Answered by AI
Is there precedent for the use of Niagen in a clinical setting?
"As of now, there are 16 ongoing studies on Niagen®, with 1 in Phase 3. Though a few of the trials for Niagen® originate from Winston-Salem, NC, 20 different sites are running investigations into Niagen®."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger